AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22136298 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) group
Number of subjects: 1021
Study 22136298 — intervention group
Group type: COMPARATOR
Intervention: Minimum Intervention (MI) group
Number of subjects: 1021
Study 22136298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EI and MI groups
Number of subjects: 1021
Study 18679829 — intervention group
Group type: EXPERIMENTAL
Intervention: Written educational information on cancer genetics
Number of subjects: 379
Study 18679829 — intervention group
Group type: COMPARATOR
Intervention: No educational information
Number of subjects: 379
Study 17328583 — intervention group
Group type: EXPERIMENTAL
Intervention: AZSR (extended-release microsphere formulation of azithromycin)
Number of subjects: 377
Study 17328583 — intervention group
Group type: EXPERIMENTAL
Intervention: AZSR
Number of subjects: 377
Study 17328583 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 377
Study 17328583 — intervention group
Group type: COMPARATOR
Intervention: Standard meal
Number of subjects: 377
Study 17328583 — intervention group
Group type: COMPARATOR
Intervention: AZSR with antacid
Number of subjects: 377
Study 14968129 — intervention group
Group type: EXPERIMENTAL
Intervention: PROT- diet (15% protein, 54% CHO)
Number of subjects: 121
Study 14968129 — intervention group
Group type: EXPERIMENTAL
Intervention: PROT+ diet (19% protein, 50% CHO)
Number of subjects: 121
Study 14968129 — intervention group
Group type: COMPARATOR
Intervention: Both diets (PROT- and PROT+)
Number of subjects: 121
Study 11965463 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum (12 mmHg)
Number of subjects: 34
Study 11965463 — intervention group
Group type: COMPARATOR
Intervention: Abdominal wall retraction (6-10 kps)
Number of subjects: 34
Study 9749496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense follow-up (Group B)
Number of subjects: 207
Study 9749496 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up (Group A)
Number of subjects: 207
Study 7524607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone (7-14 mg m-2), Methotrexate (35 mg m-2, max 50 mg), Mitomycin (7 mg m-2) with filgrastim (5 micrograms kg-1)
Number of subjects: 24
Study 7524607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone (7 mg m-2)
Number of subjects: 24
Study 7524607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone (10 mg m-2)
Number of subjects: 24
Study 7524607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone (12 mg m-2)
Number of subjects: 24
Study 7524607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone (14 mg m-2)
Number of subjects: 24
Study 2884788 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-antihistamine preparation terfenadine
Number of subjects: 0
Study 2884788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of H1-antihistamine terfenadine and H2-antihistamine ranidine
Number of subjects: 0
Study 2884788 — intervention group
Group type: COMPARATOR
Intervention: H2-antihistamine preparation ranidine
Number of subjects: 0
Study 2884788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30473186 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal RSV vaccination
Number of subjects: 6196
Study 30473186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 6196
Study 27498085 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% H2O2 for 20min followed by ozone for 60s
Number of subjects: 26
Study 27498085 — intervention group
Group type: COMPARATOR
Intervention: 38% H2O2 for 20min only (Control)
Number of subjects: 26
Study 24928191 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray and stretch
Number of subjects: 70
Study 24928191 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 70
Study 24928191 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 70
Study 22607853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10900
Study 22607853 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (standard of care)
Number of subjects: 10900
Study 19914598 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol at .25 g/kg
Number of subjects: 24
Study 19914598 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol at .5 g/kg
Number of subjects: 24
Study 19914598 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol at .75 g/kg
Number of subjects: 24
Study 19914598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18655556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with hypha cordyceps (0.33 g per capsule, 3 capsules per day) and ginkgo leaf tablet (0.23 g per tablet, 1 tablet per day) for 3 months
Number of subjects: 65
Study 18655556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 65
Study 16192842 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid titration group (RTG) - Quetiapine 200 mg/day on day 1; 400 mg/day on day 2; 600 mg/day on day 3
Number of subjects: 0
Study 16192842 — intervention group
Group type: COMPARATOR
Intervention: Conventional titration group (CTG) - Quetiapine 50 mg/day on day 1; 100 mg/day on day 2; 200 mg/day on day 3; 300 mg/day on day 4; 400 mg/day on day 5
Number of subjects: 0
Study 11875640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (females 0.35 g/kg; males 0.45 g/kg)
Number of subjects: 28
Study 11875640 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 28
Study 11875640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 28
Study 10609199 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular bag fixation (Group A)
Number of subjects: 20
Study 10609199 — intervention group
Group type: COMPARATOR
Intervention: Ciliary sulcus fixation (Group B)
Number of subjects: 20
Study 7814785 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 70
Study 7814785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 70
Study 7814785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients under age 60
Number of subjects: 70
Study 7814785 — intervention group
Group type: COMPARATOR
Intervention: Normotensive subjects under age 60
Number of subjects: 70
Study 7814785 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects over age 60
Number of subjects: 70
Study 7814785 — intervention group
Group type: EXPERIMENTAL
Intervention: QT/QS2 ratio changes
Number of subjects: 70
Study 1793726 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeniplatin at doses ranging from 8 to 145 mg/m2, given as a 60- to 90-min i.v. infusion every 3 weeks
Number of subjects: 46
Study 7198436 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometric screenings
Number of subjects: 288
Study 31448513 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/d; 3 weeks on/1 week off) plus letrozole (2.5 mg/d, continuous)
Number of subjects: 507
Study 31448513 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/d; 3 weeks on/1 week off) plus fulvestrant (500 mg)
Number of subjects: 507
Study 31448513 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib plus fulvestrant
Number of subjects: 507
Study 30793375 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-action video (n = 755)
Number of subjects: 2261
Study 30793375 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated video (n = 753)
Number of subjects: 2261
Study 30793375 — intervention group
Group type: COMPARATOR
Intervention: CDC wellness information (Control, n = 753)
Number of subjects: 2261
Study 30793375 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-action video
Number of subjects: 2261
Study 30793375 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated video
Number of subjects: 2261
Study 30793375 — intervention group
Group type: COMPARATOR
Intervention: CDC text
Number of subjects: 2261
Study 29258572 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin/ticagrelor
Number of subjects: 300
Study 29258572 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin/clopidogrel
Number of subjects: 300
Study 29258572 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin plus ezetimibe/ticagrelor
Number of subjects: 300
Study 29258572 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin plus ezetimibe/clopidogrel
Number of subjects: 300
Study 29258572 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 300
Study 26105004 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital nursing intervention delivered by a trained nurse practitioner according to self-regulatory theory
Number of subjects: 82
Study 26105004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 82
Study 24939519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM) intervention
Number of subjects: 34
Study 24939519 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 34
Study 22784653 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for 5 sessions every other day
Number of subjects: 28
Study 22784653 — intervention group
Group type: COMPARATOR
Intervention: CO(2) laser therapy
Number of subjects: 28
Study 18829008 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss surgery (bariatric surgery) resulting in >25% reduction of initial body weight
Number of subjects: 25
Study 17967652 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered physiological saline
Number of subjects: 80
Study 17967652 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered hypertonic saline
Number of subjects: 80
Study 15156249 — intervention group
Group type: EXPERIMENTAL
Intervention: Aescin + essential phospholipids (AEPL) topical gel
Number of subjects: 0
Study 11497197 — intervention group
Group type: EXPERIMENTAL
Intervention: High pulse pressure (PP)
Number of subjects: 4736
Study 11497197 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP), pulse pressure (PP), and mean arterial pressure (MAP)
Number of subjects: 4736
Study 11497197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP)
Number of subjects: 4736
Study 11497197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure (PP)
Number of subjects: 4736
Study 9510100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment with fluences ranging from 3-6.5 J/cm2
Number of subjects: 15
Study 9510100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment
Number of subjects: 15
Study 8296738 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise training program using wheelchair ergometry
Number of subjects: 88
Study 8296738 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary care (Control)
Number of subjects: 88
Study 8296738 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Home exercise training and Control)
Number of subjects: 88
Study 2566879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg QD for 2 days)
Number of subjects: 10
Study 2566879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30572482 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin training combined with CBT
Number of subjects: 120
Study 30572482 — intervention group
Group type: COMPARATOR
Intervention: Baduanjin training
Number of subjects: 120
Study 30572482 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 120
Study 27464582 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1226 (4%, 8%, or 12% CO2) administered by nebulization over a 2-minute period
Number of subjects: 36
Study 27464582 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered by nebulization over a 2-minute period
Number of subjects: 36
Study 23777653 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall compression (HFCWC) therapy
Number of subjects: 22
Study 21733334 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein and low-glycaemic index diet
Number of subjects: 96
Study 21733334 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 96
Study 21733334 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein and high-glycaemic index diet
Number of subjects: 96
Study 21733334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 96
Study 21079179 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100-200 mg daily)
Number of subjects: 20
Study 21079179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18772858 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose water
Number of subjects: 15
Study 18772858 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 15
Study 15189750 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 133
Study 15189750 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin lispro 25 (Mix25)
Number of subjects: 133
Study 15189750 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 133
Study 15189750 — intervention group
Group type: COMPARATOR
Intervention: Mix25
Number of subjects: 133
Study 15189750 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexPen
Number of subjects: 133
Study 15189750 — intervention group
Group type: COMPARATOR
Intervention: Humalog Pen
Number of subjects: 133
Study 11689745 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (interval training, four times 4 min at 90‐95% of maximal heart rate, with a 3‐min jog in between, twice per week for 8 weeks)
Number of subjects: 19
Study 11689745 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 19
Study 11689745 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 9730298 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum soluble CD23 levels in lepromatous leprosy (LL)
Number of subjects: 2
Study 9730298 — intervention group
Group type: COMPARATOR
Intervention: Serum soluble CD23 levels in tuberculoid leprosy (TL)
Number of subjects: 2
Study 9730298 — intervention group
Group type: COMPARATOR
Intervention: Serum soluble CD23 levels in healthy controls
Number of subjects: 2
Study 7987090 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine prophylaxis (oral from 14th gestational week and intravenous during delivery)
Number of subjects: 0
Study 2738979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubing changed every 24 hours
Number of subjects: 101
Study 2738979 — intervention group
Group type: COMPARATOR
Intervention: Tubing changed every 48 hours
Number of subjects: 101
Study 31735521 — intervention group
Group type: EXPERIMENTAL
Intervention: Colocystoplasty (CCP)
Number of subjects: 35
Study 31735521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocystoplasty (GCP)
Number of subjects: 35
Study 31735521 — intervention group
Group type: COMPARATOR
Intervention: Control (no malignancy)
Number of subjects: 35
Study 29722947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care intervention including knowledge, skills, diet, exercise, medication, and psychology through one-to-one consultation, individualized or group communication, establishing files, telephone follow-up, and WeChat guidance.
Number of subjects: 600
Study 29722947 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without nursing intervention).
Number of subjects: 600
Study 25846251 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (ICBT) plus standard care (SC)
Number of subjects: 221
Study 25846251 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual addiction counseling (IAC) plus standard care (SC)
Number of subjects: 221
Study 25846251 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 221
Study 25846251 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (ICBT)
Number of subjects: 221
Study 25846251 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual addiction counseling (IAC)
Number of subjects: 221
Study 23331240 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste (TAP)
Number of subjects: 180
Study 23331240 — intervention group
Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP)
Number of subjects: 180
Study 23331240 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste [Ca(OH)₂]
Number of subjects: 180
Study 23331240 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 180
Study 21883952 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor ultrasound assessment of ARA at rest
Number of subjects: 24
Study 21883952 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor ultrasound assessment of ARA during contraction
Number of subjects: 24
Study 21883952 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor ultrasound assessment of LPA at rest
Number of subjects: 24
Study 21883952 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor ultrasound assessment of LPA during contraction
Number of subjects: 24
Study 21883952 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor ultrasound assessment of LPA excursion
Number of subjects: 24
Study 21883952 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ARA with pain report
Number of subjects: 24
Study 21883952 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ARA with sexual dysfunction
Number of subjects: 24
Study 21883952 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of anxiety with ARA
Number of subjects: 24
Study 21883952 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of anxiety with LPA
Number of subjects: 24
Study 19929251 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron in combination with dexamethasone
Number of subjects: 0
Study 19929251 — intervention group
Group type: COMPARATOR
Intervention: First generation 5-HT3 receptor antagonists
Number of subjects: 0
Study 17044900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral baclofen
Number of subjects: 15
Study 17044900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15611807 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom resolution in patients with Mycoplasma pneumoniae pneumonia
Number of subjects: 76
Study 10770746 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome vaccine (0.5 ml on study day 0 or 0.25 ml on days 0 and 28)
Number of subjects: 64
Study 10770746 — intervention group
Group type: COMPARATOR
Intervention: Subunit vaccine (0.5 ml on day 0 for older children and 0.25 ml on days 0 and 28 for younger children)
Number of subjects: 64
Study 10770746 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome vaccine
Number of subjects: 64
Study 10770746 — intervention group
Group type: COMPARATOR
Intervention: Subunit vaccine
Number of subjects: 64
Study 9311548 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphide exposure
Number of subjects: 86
Study 8325315 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate
Number of subjects: 21
Study 8325315 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 21
Study 3539171 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg etretinate daily
Number of subjects: 20
Study 3539171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29415824 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional virtual reconstruction and volumetric analysis of control volume segments
Number of subjects: 20
Study 26960060 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 516
Study 26960060 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 516
Study 26960060 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (moderate-to-severe renal impairment)
Number of subjects: 516
Study 26960060 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole (moderate-to-severe renal impairment)
Number of subjects: 516
Study 26960060 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (BMI ≥30 kg/m²)
Number of subjects: 516
Study 26960060 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole (BMI ≥30 kg/m²)
Number of subjects: 516
Study 26960060 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (age >65 years)
Number of subjects: 516
Study 26960060 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole (age >65 years)
Number of subjects: 516
Study 24903987 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular mid-septal pacing (RVMSP)
Number of subjects: 92
Study 24903987 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical pacing (RVAP)
Number of subjects: 92
Study 22323712 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to trained V1 location within 45 min of training sessions.
Number of subjects: 0
Study 22323712 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the location targeted by TMS followed by training in a second location before TMS.
Number of subjects: 0
Study 20180695 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of dried modified Saccharomyces cerevisiae oral fermentate (EpiCor)
Number of subjects: 116
Study 20180695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 19127914 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaojin needling method
Number of subjects: 58
Study 19127914 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture method
Number of subjects: 58
Study 15249749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe treatment
Number of subjects: 74
Study 15249749 — intervention group
Group type: COMPARATOR
Intervention: Conventional oncology studies
Number of subjects: 74
Study 11522552 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstention from coffee for 6 weeks
Number of subjects: 191
Study 11522552 — intervention group
Group type: COMPARATOR
Intervention: 1-3 cups of coffee (175-525 mL/d) for 6 weeks
Number of subjects: 191